Erythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression

Abstract Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) share some similar pathological mechanisms. In current study, we intend to investigate the impact of AR on CRS. In addition, we explored the efficacy of erythromycin (EM) treatment on CRS mice with or without AR (CRSwoAR, CRSwAR). Stud...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ting-Ting Yen, Rong-San Jiang, Ching-Yun Chang, Chih-Ying Wu, Kai-Li Liang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1ac077b3505a4951a9c3a19e2b3950bd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1ac077b3505a4951a9c3a19e2b3950bd
record_format	dspace
spelling	oai:doaj.org-article:1ac077b3505a4951a9c3a19e2b3950bd2021-11-08T10:56:13ZErythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression10.1038/s41598-021-01192-82045-2322https://doaj.org/article/1ac077b3505a4951a9c3a19e2b3950bd2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01192-8https://doaj.org/toc/2045-2322Abstract Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) share some similar pathological mechanisms. In current study, we intend to investigate the impact of AR on CRS. In addition, we explored the efficacy of erythromycin (EM) treatment on CRS mice with or without AR (CRSwoAR, CRSwAR). Study subjects were divided into control, CRSwoAR, and CRSwAR groups. Experimental mice were divided similarly into control, CRSwoAR, and CRSwAR groups. In addition, CRS mice were treated with EM at 0.75, 7.5, or 75 mg/kg or with dexamethasone (Dex) at 1 mg/kg. In our results, allergy exacerbates inflammation that was evident in nasal histology and cytokine expression both in patients and in mice with CRS. Dex 1 mg/kg, EM 7.5 or 75 mg/kg treatments significantly inhibited serum IgE and IgG2a in CRS mice. EM-treated CRS mice had significantly elevated IL-10 levels and had a reversal of Th-1/Th-2 cytokine expression in nasal-associated lymphoid tissue. MUC5AC expressions were significantly reduced in the 7.5 or 75 mg/kg EM-treated mice compared with untreated mice. EM showed inhibitions on immunoglobulin production and mucus secretion stronger than Dex. We concluded that comorbid AR enhanced inflammation of CRS. EM and Dex treatments showed similar anti-inflammatory effects on CRS but through partly different mechanisms.Ting-Ting YenRong-San JiangChing-Yun ChangChih-Ying WuKai-Li LiangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ting-Ting Yen Rong-San Jiang Ching-Yun Chang Chih-Ying Wu Kai-Li Liang Erythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression
description	Abstract Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) share some similar pathological mechanisms. In current study, we intend to investigate the impact of AR on CRS. In addition, we explored the efficacy of erythromycin (EM) treatment on CRS mice with or without AR (CRSwoAR, CRSwAR). Study subjects were divided into control, CRSwoAR, and CRSwAR groups. Experimental mice were divided similarly into control, CRSwoAR, and CRSwAR groups. In addition, CRS mice were treated with EM at 0.75, 7.5, or 75 mg/kg or with dexamethasone (Dex) at 1 mg/kg. In our results, allergy exacerbates inflammation that was evident in nasal histology and cytokine expression both in patients and in mice with CRS. Dex 1 mg/kg, EM 7.5 or 75 mg/kg treatments significantly inhibited serum IgE and IgG2a in CRS mice. EM-treated CRS mice had significantly elevated IL-10 levels and had a reversal of Th-1/Th-2 cytokine expression in nasal-associated lymphoid tissue. MUC5AC expressions were significantly reduced in the 7.5 or 75 mg/kg EM-treated mice compared with untreated mice. EM showed inhibitions on immunoglobulin production and mucus secretion stronger than Dex. We concluded that comorbid AR enhanced inflammation of CRS. EM and Dex treatments showed similar anti-inflammatory effects on CRS but through partly different mechanisms.
format	article
author	Ting-Ting Yen Rong-San Jiang Ching-Yun Chang Chih-Ying Wu Kai-Li Liang
author_facet	Ting-Ting Yen Rong-San Jiang Ching-Yun Chang Chih-Ying Wu Kai-Li Liang
author_sort	Ting-Ting Yen
title	Erythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression
title_short	Erythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression
title_full	Erythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression
title_fullStr	Erythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression
title_full_unstemmed	Erythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression
title_sort	erythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1ac077b3505a4951a9c3a19e2b3950bd
work_keys_str_mv	AT tingtingyen erythromycinreducesnasalinflammationbyinhibitingimmunoglobulinproductionattenuatingmucussecretionandmodulatingcytokineexpression AT rongsanjiang erythromycinreducesnasalinflammationbyinhibitingimmunoglobulinproductionattenuatingmucussecretionandmodulatingcytokineexpression AT chingyunchang erythromycinreducesnasalinflammationbyinhibitingimmunoglobulinproductionattenuatingmucussecretionandmodulatingcytokineexpression AT chihyingwu erythromycinreducesnasalinflammationbyinhibitingimmunoglobulinproductionattenuatingmucussecretionandmodulatingcytokineexpression AT kaililiang erythromycinreducesnasalinflammationbyinhibitingimmunoglobulinproductionattenuatingmucussecretionandmodulatingcytokineexpression
_version_	1718442500702601216

Erythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression

Ejemplares similares